Clobetasone Butyrate 0.05% Cream

Vehicle (base cream)

Clobetasone Butyrate 0.05% Cream

Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.

Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.

Investigator assessed surface & severity of erythema, induration/papulation, excoriation & lichenification in four body areas using EASI: head/neck, upper extremities, trunk & lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk & 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 7 minus sum of score at baseline) *100/sum of score after day 7. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.

The IGA was used to determine disease severity in a given time and describe severity of eczema using scale of 0 to 6 as follows: 0 Clear:=No inflammatory signs of eczema; 1 Almost clear=Just perceptible erythema and just perceptible papulation/infiltration; 2 Mild:=Mild erythema and mild papulation/infiltration; 3 Moderate:=Moderate erythema, and moderate papulation/infiltration; 4 Severe= Severe erythema, and severe papulation/infiltration; 5 Very Severe=Very severe erythema, and very severe papulation/infiltration with oozing/crusting. Lesser score indicate lesser disease severity.